Isolation and Characterization of Urinary Extracellular Vesicles from Healthy Donors and Patients with Castration-Resistant Prostate Cancer

被引:14
|
作者
Lee, Haneul [1 ]
Kang, Su Jin [1 ]
Lee, Jimin [2 ]
Park, Kyong Hwa [2 ]
Rhee, Won Jong [1 ,3 ,4 ]
机构
[1] Incheon Natl Univ, Dept Bioengn & Nanobioengn, Incheon 22012, South Korea
[2] Korea Univ, Dept Internal Med, Div Oncol Hematol, Coll Med, Seoul 02841, South Korea
[3] Incheon Natl Univ, Div Bioengn, Incheon 22012, South Korea
[4] Incheon Natl Univ, Res Ctr Bio Mat & Proc Dev, Incheon 22012, South Korea
基金
新加坡国家研究基金会;
关键词
liquid biopsy; extracellular vesicle; prognosis; urine; castration-resistant prostate cancer; MICRORNA BIOMARKERS; PROGRESSION; MIRNAS;
D O I
10.3390/ijms23137134
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate cancer (PCa) is the most commonly diagnosed malignancy among men in developed countries. The five-year survival rate for men diagnosed with early-stage PCa is approximately 100%, while it is less than 30% for castration-resistant PCa (CRPC). Currently, the detection of prostate-specific antigens as biomarkers for the prognosis of CRPC is criticized because of its low accuracy, high invasiveness, and high false-positive rate. Therefore, it is important to identify new biomarkers for prediction of CRPC progression. Extracellular vesicles (EVs) derived from tumors have been highlighted as potential markers for cancer diagnosis and prognosis. Specifically, urinary EVs directly reflect changes in the pathophysiological conditions of the urogenital system because it is exposed to prostatic secretions. Thus, detecting biomarkers in urinary EVs provides a promising approach for performing an accurate and non-invasive liquid biopsy for CPRC. In this study, we effectively isolated urinary EVs with low protein impurities using size-exclusion chromatography combined with ultrafiltration. After EV isolation and characterization, we evaluated the miRNAs in urinary EVs from healthy donors and patients with CRPC. The results indicated that miRNAs (miR-21-5p, miR-574-3p, and miR-6880-5p) could be used as potential biomarkers for the prognosis of CRPC. This analysis of urinary EVs contributes to the fast and convenient prognosis of diseases, including CRPC, in the clinical setting.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Olaparib in Metastatic Castration-Resistant Prostate Cancer
    Smith, Thomas J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1175 - 1175
  • [42] Olaparib in metastatic castration-resistant Prostate Cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [43] Castration-Resistant Prostate Cancer: AUA Guideline
    Cookson, Michael S.
    Roth, Bruce J.
    Dahm, Philipp
    Engstrom, Christine
    Freedland, Stephen J.
    Hussain, Maha
    Lin, Daniel W.
    Lowrance, William T.
    Murad, Mohammad Hassan
    Oh, William K.
    Penson, David F.
    Kibel, Adam S.
    JOURNAL OF UROLOGY, 2013, 190 (02): : 429 - 438
  • [44] Biomarkers in Metastatic Castration-resistant Prostate Cancer
    Miller, K.
    AKTUELLE UROLOGIE, 2015, 46 (01) : 66 - 70
  • [45] The DNA methylome of castration-resistant prostate cancer
    Kleb, Brittney N.
    Estecio, Marcos
    Zhang, Jiexin
    Tzelepi, Vasso
    Chung, Woonbok
    Maity, Sankar
    Logothetis, Christopher
    Troncoso, Patricia
    Navone, Nora
    Jelinek, Jaroslav
    Liang, Shoudan
    Issa, Jean-Pierre
    Aparicio, Ana
    CANCER RESEARCH, 2012, 72
  • [46] Enzalutamide in Castration-Resistant Prostate Cancer Reply
    Hussain, Maha
    Saad, Fred
    Sternberg, Cora N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (14): : 1381 - 1381
  • [47] Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate
    Yamamoto, Akiyuki
    Kato, Masashi
    Matsui, Hirotaka
    Ishida, Ryo
    Kimura, Tohru
    Funahashi, Yasuhito
    Sassa, Naoto
    Matsukawa, Yoshihisa
    Kamihira, Osamu
    Hattori, Ryohei
    Gotoh, Momokazu
    Tsuzuki, Toyonori
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (03) : 584 - 590
  • [48] Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate
    Akiyuki Yamamoto
    Masashi Kato
    Hirotaka Matsui
    Ryo Ishida
    Tohru Kimura
    Yasuhito Funahashi
    Naoto Sassa
    Yoshihisa Matsukawa
    Osamu Kamihira
    Ryohei Hattori
    Momokazu Gotoh
    Toyonori Tsuzuki
    International Journal of Clinical Oncology, 2018, 23 : 584 - 590
  • [49] Predicting the future in castration-resistant prostate cancer
    Verhagen, Paul
    LANCET ONCOLOGY, 2009, 10 (03): : 201 - 202
  • [50] Advances in metastatic castration-resistant prostate cancer
    Kentepozidis, Nikolaos
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S108 - S108